Founded in 1996, Santarus Inc. is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of proprietary products and therapies that have the potential to treat gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD). The company's main focus lies on the commercialization of proprietary immediate-release proton pump inhibitor (PPI) products. PPIs are the most frequently prescribed drugs for the treatment of many upper gastrointestinal (GI) diseases and disorders. Santarus offers the Zegerid family of products, which are proprietary immediate-release formulations that combine omeprazole, a PPI, and one or more antacids. These products are approved by the FDA for the treatment or reduction of the risk of a variety of upper GI diseases and disorders. Zegerid is currently marketed in capsule and powder for oral suspension dosage forms.
In 2006, Santarus earned $49.2 million in revenue, 93.4% of which came from product sales. Other revenues accounted for the balance 6.6%. Santarus has licensing agreements with two major pharmaceutical companies, Schering-Plough and GlaxoSmithKline, for Zegerid. Besides this, the company has co-promotion agreements for two products Naprelan and the EZ-Prep Bowel Cleansing system. Headquartered in San Diego, California, Santarus currently employs 347 people.